A clinical trial of 3 doses of transdermal 17β-estradiol for preventing postmenopausal bone loss: A preliminary study

Journal of the Chinese Medical Association

Volumn 70, Issue 5, 2007, Pages 200-206

  Yang, Tzay Shing ^a,b   Chen, Yi Jen ^a,b   Liang, Wei Hsing ^a,b   Chang, Cheng Yen ^a,b   Tai, Ling Chen ^a,b   Chang, Sheng Pin ^a,b   Ng, Heung Tat ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Bone mineral density; Effective low dose; Estradiol gel; Menopause; Oophorectomy; Quantitative computed tomography

Indexed keywords

CALCIUM CARBONATE; ESTRADIOL; ESTRIOL; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VERTEBRA;

EID: 34250680937     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70358-2     Document Type: Article

References (43)

1. Kanis JA. Maintenance of bone mass. In: Kanis JA, ed. Textbook of Osteoporosis. London: Blackwell Science, 1996:1-28.
2. Pastoureau PD, Arlot ME, Caulin F, Barlet JP, Meunier PJ, Delmas PD. Effects of oophorectomy on biochemical and histological indices of bone turnover in ewes. J Bone Miner Res 1989; 477:S237.
3. Thompson DD, Seedor JG, Quartuccio H, Solomon H, Fioravanti C, Davidson J, Klein H, et al. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res 1992;7:95140.
4. Manolagas SC, Filka RL. Cytokines, hematopoiesis, osteoclastogenesis and oestrogens. Calcif Tissue Int 1992;50:199-202.
5. Meema HE, Bunker ML, Meema S. Loss of compact bone due to menopause. Obstet Gynecol 1965;26:333-43.
6. Estell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-45.
7. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of post-menopausal osteoporosis by estrogen. Lancet 1976;1:1038-41.
8. Kreiger N, Kelsey JK, Holford TR, O'Connor T. An epidemiological study of hip fracture in postmenopausal women. Am J Epidemiol 1982;116:141-8.
9. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 1987;317:1169-74.
10. Geola FL, Frumar AM, Tataryn IV, Lu KH, Hershman JM, Eggena P, Sambhi MP, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980;51:620-5.
11. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, et al. Biological effects of transdermal estradiol. N Engl J Med 1986;314:1615-20.
12. Ribot C, Tremollieres F, Pouiller JU, Louvet JP, Peyron R. Preventive effects of transdermal administration of 17-β estradiol on postmenopausal bone loss: a 2-year prospective study. Gyn Endoc 1989;3:259-67.
13. NG HT, Change SP, Yang TS, Cho MP, Wei TC. Estradiol administered in a percutaneous gel for the prevention of postmenopausal bone loss. Asia-Oceania J Obstet Gynecol 1993; 19:115-9.
14. Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, et al. Hormone replacement therapy and risk of hip fracture. Popular based case-control study. BMJ 1998;316:1858-63.
15. Horsman A, Jones M, Francos R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med 1983; 309:1405-7.
16. Lindsay R, Hart DM, Clark DK. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759-63.
17. Genant HK, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H, Downs R, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch Intern Med 1997;157:2609-15.
18. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17-β estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993;168:114-21.
19. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Obstet Gyneco1 1999;94:330-6.
20. Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. J Chin Med Assoc 1995;55:386-91.
21. Ettinger B. Use of low-dosage 17-β-estradiol for the prevention of osteoporosis. Clin Ther 1993;15:950-62.
22. Chakravarti S, Collins WP, Newton JR. Endocrine changes and symptomatology after oophorectomy in postmenopausal women. Br J Obstet Gynaecol 1978;84:769-75.
23. Richelson LS, Wahner HW, Melton LJ, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984;311:1273-5.
24. Ohta H, Masuzawa T, Ikeda T, Suda Y, Makita K, Nozawa S. Which is more osteoporosis-inducing, menopause or oophorectomy? Bone Miner 1992;19:273-85.
25. Judd HL, Judd GE, Lucas WE, Yen SSC. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974;39:1020-4.
26. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo study. J Clin Endocrinol Metab 2000;85:645-51.
27. Arisaka O, Arisaka M, Nakayama Y, Fujiwara S, Yabuta K. Effect of testosterone on bone density and bone metabolism in adolescent male hypogonadism. Metabolism 1995;44:419-23.
28. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-61.
29. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-98.
30. Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, Cooney KA. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999;54: 607-11.
31. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001;57:127-32.
32. Stuaub B, Muller M, Schrader M, Heicappell R, Miller K. Osteoporosis and mild metabolic acidosis in the rat after orchiectomy and their prevention: should prophylactic therapy be administered to patients with androgen deprivation? J Urology 2001;165:1783-9.
33. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, Riggs BL, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 1989;86:854-7.
34. Anderson FH, Francis RM, Selby PL, Cooper C. Sex hormones and osteoporosis in men. Calcif Tissue Int 1998;62:185-8.
35. Francis RM. The effects of testosterone on osteoporosis in men. Clin Endocrinol 1999;50:411-4.
36. Arisaka O, Hoshi M, Kanazawa S, Numata M, Nakajima D, Kanno S, Negishi M, et al. Effect of adrenal androgen and estrogen on bone maturation and bone mineral density. Metabolism 2001;50:377-9.
37. Kanis JA. Assessment of bone mass. In: Kanis JA, ed. Textbook of Osteoporosis. London: Blackwell Science, Ltd., 1996;71-105.
38. Cetin A, Erturk H, Celiker R, Sivri A, Hascelik Z. The role of quantitative ultrasound in predicting osteoporosis defined by dual X-ray absorptiometry. Rheumatol Int 2001;20:55-9.
39. Virdis A, Ghiadoni L, Pinto S, Lombardo M, Petraglia F, Gennazzani A, Buralli S, et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation 2000;101:2258-63.
40. Schairer C, Adami HO, Hoova R, Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 1997;8:59-65.
41. The ESHRE Capri Workshop Group. Continuation rates for oral contraceptives and hormone replacement therapy. Hum Reprod 2000;15:1865-71.
42. Belehetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71.
43. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245-51.